PSA and Ki-67 tumour markers may identify high-risk metastatic castration-sensitive prostate cancer and inform treatment ...

New research links PSA and PSA density to long-term prostate cancer risk, supporting risk-adapted screening strategies. Learn more about the 20-year findings.

A set of genes may identify a prostate cancer subtype in African American patients that needs aggressive treatment. Specific genes may signal aggressive prostate cancer (PCa) in African American men, ...

Researchers at the Johns Hopkins Kimmel Cancer Center, Johns Hopkins All Children's Hospital and four other institutions have devised a novel method to test for prostate cancer using biomarkers ...

Prostate cancer researchers have discovered biomarkers using non-invasive liquid biopsies to identify aggressive disease before surgery. The research, published online today in Nature Communications, ...

A third of patients with high-risk prostate cancer identified as biomarker-negative by an artificial intelligence (AI)–derived tool were safe to forgo long-term androgen deprivation therapy (ADT).

Urine panel had AUC of 0.96 and 0.92 with development and validation datasets, respectively, compared with 0.83 and 0.76 for urinary PCA3 RNA. HealthDay News — A urine-based biomarker panel has high ...

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing As evidenced by the findings from ...

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 Findings are among nine ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...